Future research is likely to focus on enhancing the specificity and efficacy of arginine depletion strategies. This could involve the engineering of more stable and less immunogenic enzyme variants, as well as the development of targeted delivery systems that can localize the therapeutic effect to the tumor site. Combination therapies that integrate arginine deprivation with other treatment modalities, such as chemotherapy or immunotherapy, are also being explored to improve clinical outcomes.
